Adlai Nortye (ANL) EPS (Basic) (2024)
Adlai Nortye's (ANL) quarterly EPS (Basic) came in at -$0.0 in Q4 2024.
Adlai Nortye (ANL) EPS (Basic) (2024) Analysis & Trends
Adlai Nortye (ANL) has 1 years of EPS (Basic) data on file, last reported at -$0.0 in Q4 2024.
- On a quarterly basis, EPS (Basic) changed N/A year-over-year to -$0.0 in Q4 2024; TTM through Dec 2025 was -$0.0, a 0.15% change from a year earlier, with the FY2025 full-year figure at -$0.37, up 31.61% from the prior year.
- EPS (Basic) for Q4 2024 stood at -$0.0.
- Over the last five years, EPS (Basic) for ANL reached as high as -$0.0 in Q4 2024 and fell as low as -$0.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.16 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 0.00 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 0.00 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 7.59 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -2.29 |
| 10 | Adlai Nortye | 1.27 Bn | 1.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |